Skip to main content

ROS1 fusion-positive NSCLC

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Luis Paz-Ares, Jaime Schneider, and Benjamin Besse discuss the management of ROS1 fusion-positive NSCLC in patients based in Europe and the USA.

00:00 Introduction 
01:12 Testing for ROS1 fusions
08:43 Treatment of ROS1 fusion-positive NSCLC
14:17 CNS metastases
16:15 On progression
19:44 Next-generation agents
23:22 Thromboprophylaxis
25:25 Chemotherapy and immunotherapy
31:32 The need to understand etiology
32:45 Combating resistance


Meet the faculty

  • Luis Paz-Ares

    Luis Paz-Ares is currently Chair of the Medical Oncology Department at the Hospital Doce de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), all in Madrid, Spain. Full biography

  • Jaime Schneider

    Dr Jaime Schneider is a thoracic oncologist at the Massachusetts General Hospital (MGH) in Boston, USA, and an instructor in medicine at Harvard Medical School. Full biography

  • Benjamin Besse

    Prof. Benjamin Besse is the Director of Clinical Research at the Gustave Roussy Institute and is Professor of Medical Oncology at Paris-Saclay University, France. Full biography

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Faculty disclosures

Faculty disclosures

Luis Paz-Ares

Leadership: Genomica (external member of the board), Altum Sequencing (founding partner and member of the board)

Travel, accommodation, expenses: Roche, AstraZeneca, MSD, Bristol-Myers Squibb, Lilly, Pfizer

Honoraria: Roche/Genentech, Lilly, Pfizer, Bristol-Myers Squibb, MSD, BMS, AstraZeneca, Merck Serono, PharmaMar, Novartis, Celgene, Amgen, Mirati, Abbvie

Other relationship (immediate family member): Novartis, Ipsen, Pfizer, Servier, Sanofi, Roche, Amgen, Merck

Jaime Schneider

Declares no conflict of interest

Benjamin Besse

Sponsored Research at Gustave Roussy Cancer Center: 4D Pharma, Abbvie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Chugai pharmaceutical, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, EISAI, Genzyme Corporation, GSK, Inivata, IPSEN, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals, Turning Point Therapeutics

Funding and disclaimer

Funding and disclaimer

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Any information provided and opinions expressed do not necessarily reflect the views of Springer Healthcare Limited (part of the Springer Nature Group) or the Medicine Matters Editorial Board. Springer Healthcare Limited, Springer Nature Limited and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.

Attention: This content is intended for healthcare professionals only

In order to proceed please confirm whether you are a healthcare professional.

No, I am not a
healthcare professional
Yes, I am a
healthcare professional